Liquid crystal forms of cyclosporin

Abstract

This invention relates to novel, liquid crystal forms of the cyclic peptide cyclosporin and to novel powder formulations of cyclosporin prepared using this novel liquid crystal form of the drug. Methods for preparing and using these formulations are also provided. In particular, the present invention relates to dispersible spray dried particles of cyclosporin suitable for pulmonary delivery.

It is claimed:  
     
         1 . Cyclosporin in liquid crystal form.  
     
     
         2 . The cyclosporin of  claim 1  wherein the cyclosporin is cyclosporin A.  
     
     
         3 . The cyclosporin of  claim 1  which shows sharp peaks by small angle X-ray scattering.  
     
     
         4 . The cyclosporin of  claim 1  which is in dispersible powder form.  
     
     
         5 . The cyclosporin of  claim 1  for use as an immunosuppressive, anti-inflammatory, or anti-asthmatic agent.  
     
     
         6 . The cyclosporin of  claim 1  which is prepared by spray drying from a solvent.  
     
     
         7 . A composition for pulmonary delivery comprising liquid crystal cyclosporin in respirable powder particles.  
     
     
         8 . The composition of  claim 7  wherein the cyclosporin is cyclosporin A.  
     
     
         9 . The composition of  claim 7  which is dispersible.  
     
     
         10 . The composition of  claim 7  which further comprises a pharmaceutically acceptable excipient or carrier.  
     
     
         11 . The composition of  claim 7  which is prepared by spray drying.  
     
     
         12 . The composition of  claim 7  wherein the cyclosporin comprises at least about 40% by weight of the composition.  
     
     
         13 . The composition of  claim 7  wherein the particles in the powder have a particle size range between 0.1 and 15 μm MMD.  
     
     
         14 . The composition of  claim 7  wherein the particles have an MMAD of less than about 5 μm.  
     
     
         15 . The composition of  claim 7  which has a delivered dose efficiency of at least about 30%.  
     
     
         16 . A method for preparing the composition of  claim 7  comprising: 
 a) mixing cyclosporin with a solvent to form a solution or suspension; and  
 b) spray drying the mixture formed in step a) under conditions which provide a respirable powder.  
 
     
     
         17 . The method of  claim 16  further comprising the step of adding a pharmaceutically acceptable excipient or carrier prior to spray drying.  
     
     
         18 . The method of  claim 17  wherein said solvent comprises a solution of less than 50% water.  
     
     
         19 . The method of  claim 16  wherein the solvent is selected from the group consisting of ethanol, acetone, acetonitrile, isopropanol and methanol.  
     
     
         20 . A method of treating or preventing a condition in a subject which may be prevented or alleviated by cyclosporin, the method comprising pulmonary administration of a therapeutically effective amount of the composition of  claim 7  to a subject susceptible to or suffering from the condition.  
     
     
         21 . The method of  claim 20  wherein the condition is selected from the group consisting of asthma, transplant rejection, sarcoidosis, chronic inflammatory lung disease, chronic obstructive pulmonary disease, emphysema, primary and secondary pulmonary hypertension, cystic fibrosis, lung infections, rheumatoid arthritis and idiopathic pulmonary fibrosis.